Diabetes, Obesity and Metabolism, 25(1), 1-10
The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations
Pathogenesis of Alcoholic Liver Disease: Role of Oxidative Metabolism
For many clients, this is the point in the year when it becomes easier to make a confident, informed decision about what their body needs heading into winter
Multimodal weight loss compounds that integrate agonism at two or more receptor systems are emerging 27,43,44,45
In trials involving 176 participants across four randomized controlled studies, liraglutide was used in 58% of cases (103 participants), while semaglutide was used in 13% (23 participants)